Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells

Affiliations

Baocheng Gong: Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China
Baocheng Gong: Medical Research Center, Liaoning Key Laboratory of Research and Application of Animal Models for Environment and Metabolic Diseases, Shengjing Hospital of China Medical University, Shenyang, China
Jinhua Zhang: Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China
Zhongyan Hua: Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China
Zhongyan Hua: Medical Research Center, Liaoning Key Laboratory of Research and Application of Animal Models for Environment and Metabolic Diseases, Shengjing Hospital of China Medical University, Shenyang, China
Zhihui Liu: Cellular and Molecular Biology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
Carol J. Thiele: Cellular and Molecular Biology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
Zhijie Li: Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China
Zhijie Li: Medical Research Center, Liaoning Key Laboratory of Research and Application of Animal Models for Environment and Metabolic Diseases, Shengjing Hospital of China Medical University, Shenyang, China

Abstract

No abstracts available.

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/